Nilotinib Vs Nilotinib Plus Pegylated Interferon a (Peg-IFN) Induction and Nilotinib or Peg-IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1 Positive Chronic Myeloid Leukemia Patients in Chronic Phase (TIGER Study): The Addition of Peg-IFN Is Associated with Higher Rates of Deep Molecular Response (2019) Hochhaus A, Burchert A, Saussele S, Baerlocher GM, Brummendorf TH, Rosee PL, Heim D, et al. Conference contribution The Influence of the Age of the Bone Marrow Microenvironment on Leukaemia Progression (2019) Zanetti C, Ender J, Hartmann M, Hey J, Godavarthy PS, Weissenberger E, Kumar R, et al. Conference contribution beta(2)-m - a Trigger for NLRP3 Inflammasome Activation within Macrophages Promoting Multiple Myeloma Cell Proliferation (2019) Hofbauer D, Mougiakakos D, Büttner-Herold M, Neumann F, Nolting J, Bisht S, Zeiser R, et al. Conference contribution Mechanistic Characterization of Tafasitamab-Mediated Antibody-Dependent Cellular Phagocytosis Alone or in Combination with Lenalidomide (2019) Mougiakakos D, Völkl S, Bach C, Stoll A, Bitterer K, Beier F, Endell J, et al. Conference contribution Platelet and Immune Characteristics of Patients with Immune Thrombocytopaenia Non Responders to Therapeutic Treatments (2019) Monzon Manzano E, Justo Sanz R, Hernandez D, Alvarez Roman T, Fernandez-Bello I, Martin M, Valor L, et al. Conference contribution High Platelet Counts, Thrombosis, Bleeding Signs, and Acquired Von Willebrand Syndrome at Diagnosis of Pediatric Chronic Myeloid Leukemia (2019) Suttorp M, Knoefler R, Deutsch H, Paul F, Tiebel O, Metzler M, Millot F Conference contribution Prothrombotic State, Platelet Activation and Netosis in Systemic Lupus Erythematosus (2019) Monzon Manzano E, Fernandez-Bello I, Justo Sanz R, Valor L, Javier Lopez-Longo F, Robles A, Alvarez Roman T, et al. Conference contribution Vaccination with Live Attenuated Virus Vaccines in Four Pediatric Patients with CML While on Imatinib Treatment (2019) Da Cunha-Riehm CB, Hildebrand V, Nathrath M, Metzler M, Suttorp M Conference contribution Microenvironmental Triggers Induce a Chemoresistant, Differentiated Subset of S100A8/A9(high) AML Cells Via the Jak/STAT3 Signaling Axis (2019) Böttcher M, Panagiotidis K, Mentz K, Völkl S, Bruns H, Slany R, Mackensen A, Mougiakakos D Conference contribution The preleukemic TCF3-PBX1 gene fusion can be generated in utero and is present in ≈0.6% of healthy newborns (2019) Hein D, Dreisig K, Metzler M, Izraeli S, Schmiegelow K, Borkhardt A, Fischer U Journal article